Literature DB >> 19457663

Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking.

Harshani R Lawrence1, Zhenyu Li, M L Richard Yip, Shen-Shu Sung, Nicholas J Lawrence, Mark L McLaughlin, Gregory J McManus, Michael J Zaworotko, Saïd M Sebti, Jiandong Chen, Wayne C Guida.   

Abstract

NSC 333003 has been identified from the NCI Diversity Set as an inhibitor of the MDM2-p53 protein-protein interaction by in silico docking (virtual screening). Its potency and chemical characteristics render it well suited for lead optimization studies that can result in more potent analogs with improved drug-like properties. Its synthesis was achieved using an acid catalyzed condensation reaction from commercially available benzothiazole hydrazine and pyridyl phenyl ketone in refluxing methanol. Stereochemical implications for this compound are described.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457663      PMCID: PMC2754843          DOI: 10.1016/j.bmcl.2009.04.124

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  21 in total

1.  Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.

Authors:  C García-Echeverría; P Chène; M J Blommers; P Furet
Journal:  J Med Chem       Date:  2000-08-24       Impact factor: 7.446

2.  Molecular characterization of the hdm2-p53 interaction.

Authors:  A Böttger; V Böttger; C Garcia-Echeverria; P Chène; H K Hochkeppel; W Sampson; K Ang; S F Howard; S M Picksley; D P Lane
Journal:  J Mol Biol       Date:  1997-06-27       Impact factor: 5.469

3.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.

Authors:  Thomas A Halgren; Robert B Murphy; Richard A Friesner; Hege S Beard; Leah L Frye; W Thomas Pollard; Jay L Banks
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

4.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

5.  Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry.

Authors:  Yuen Ho; Albrecht Gruhler; Adrian Heilbut; Gary D Bader; Lynda Moore; Sally-Lin Adams; Anna Millar; Paul Taylor; Keiryn Bennett; Kelly Boutilier; Lingyun Yang; Cheryl Wolting; Ian Donaldson; Søren Schandorff; Juanita Shewnarane; Mai Vo; Joanne Taggart; Marilyn Goudreault; Brenda Muskat; Cris Alfarano; Danielle Dewar; Zhen Lin; Katerina Michalickova; Andrew R Willems; Holly Sassi; Peter A Nielsen; Karina J Rasmussen; Jens R Andersen; Lene E Johansen; Lykke H Hansen; Hans Jespersen; Alexandre Podtelejnikov; Eva Nielsen; Janne Crawford; Vibeke Poulsen; Birgitte D Sørensen; Jesper Matthiesen; Ronald C Hendrickson; Frank Gleeson; Tony Pawson; Michael F Moran; Daniel Durocher; Matthias Mann; Christopher W V Hogue; Daniel Figeys; Mike Tyers
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

Review 6.  The art and practice of structure-based drug design: a molecular modeling perspective.

Authors:  R S Bohacek; C McMartin; W C Guida
Journal:  Med Res Rev       Date:  1996-01       Impact factor: 12.944

7.  Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts.

Authors:  Thorsten Berg; Steven B Cohen; Joel Desharnais; Corinna Sonderegger; Daniel J Maslyar; Joel Goldberg; Dale L Boger; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

8.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

9.  Computational validation of the importance of absolute stereochemistry in virtual screening.

Authors:  Wesley H Brooks; Kenyon G Daniel; Shen-Shu Sung; Wayne C Guida
Journal:  J Chem Inf Model       Date:  2008-02-12       Impact factor: 4.956

10.  [Tridentate N-N-N chelating systems as potential antitumor agents].

Authors:  C Pellerano; L Savini; P Massarelli
Journal:  Farmaco Sci       Date:  1985-09
View more
  9 in total

1.  Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.

Authors:  Jason Phan; Zhenyu Li; Agnieszka Kasprzak; Baozong Li; Said Sebti; Wayne Guida; Ernst Schönbrunn; Jiandong Chen
Journal:  J Biol Chem       Date:  2009-11-12       Impact factor: 5.157

2.  Structure-based virtual screening identifies a small-molecule inhibitor of the profilin 1-actin interaction.

Authors:  David Gau; Taber Lewis; Lee McDermott; Peter Wipf; David Koes; Partha Roy
Journal:  J Biol Chem       Date:  2017-12-27       Impact factor: 5.157

Review 3.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

Review 4.  Targeting p53-MDM2-MDMX loop for cancer therapy.

Authors:  Qi Zhang; Shelya X Zeng; Hua Lu
Journal:  Subcell Biochem       Date:  2014

Review 5.  Targeting protein-protein interactions as an anticancer strategy.

Authors:  Andrei A Ivanov; Fadlo R Khuri; Haian Fu
Journal:  Trends Pharmacol Sci       Date:  2013-05-29       Impact factor: 14.819

6.  An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors.

Authors:  Xin Xue; Gang Bao; Hai-Qing Zhang; Ning-Yi Zhao; Yuan Sun; Yue Zhang; Xiao-Long Wang
Journal:  Molecules       Date:  2018-12-01       Impact factor: 4.411

Review 7.  Abrogating the Interaction Between p53 and Mortalin (Grp75/HSPA9/mtHsp70) for Cancer Therapy: The Story so far.

Authors:  Ahmed Elwakeel
Journal:  Front Cell Dev Biol       Date:  2022-04-14

Review 8.  Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials.

Authors:  Haiying Lu; Qiaodan Zhou; Jun He; Zhongliang Jiang; Cheng Peng; Rongsheng Tong; Jianyou Shi
Journal:  Signal Transduct Target Ther       Date:  2020-09-23

9.  Triapine Analogues and Their Copper(II) Complexes: Synthesis, Characterization, Solution Speciation, Redox Activity, Cytotoxicity, and mR2 RNR Inhibition.

Authors:  Iuliana Besleaga; Iryna Stepanenko; Tatsiana V Petrasheuskaya; Denisa Darvasiova; Martin Breza; Marta Hammerstad; Małgorzata A Marć; Alexander Prado-Roller; Gabriella Spengler; Ana Popović-Bijelić; Eva A Enyedy; Peter Rapta; Anatoly D Shutalev; Vladimir B Arion
Journal:  Inorg Chem       Date:  2021-07-19       Impact factor: 5.165

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.